Liberum Capital restated their buy rating on shares of Relx PLC (LON:REL) in a report issued on Monday, MarketBeat reports. They currently have a GBX 1,215 ($17.48) target price on the stock.

Several other analysts also recently weighed in on the company. Barclays restated an overweight rating and set a GBX 1,360 ($19.57) target price on shares of Relx PLC in a research note on Thursday, January 28th. Sanford C. Bernstein restated a market perform rating and set a GBX 1,175 ($16.90) target price on shares of Relx PLC in a research note on Wednesday, January 27th. Goldman Sachs restated a buy rating on shares of Relx PLC in a research note on Wednesday, January 20th. JPMorgan Chase & Co. increased their target price on Relx PLC from GBX 1,195 ($17.19) to GBX 1,240 ($17.84) and gave the company an overweight rating in a research note on Tuesday, January 19th. Finally, Investec restated a buy rating and set a GBX 1,266 ($18.21) target price on shares of Relx PLC in a research note on Wednesday, January 13th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of GBX 1,218.39 ($17.53).

Relx PLC (LON:REL) traded down 1.0586% during trading on Monday, reaching GBX 1215.0000. The company had a trading volume of 2,805,077 shares. The stock has a 50 day moving average of GBX 1,174.94 and a 200-day moving average of GBX 1,131.52. Relx PLC has a 12 month low of GBX 988.50 and a 12 month high of GBX 1,235.00. The company’s market capitalization is GBX 13.70 billion.

RELX PLC, formerly Reed Elsevier PLC, is a provider of information solutions. The Company operates in four market segments: Scientific, Technical & Medical; Risk & Business Information; Legal, and Exhibitions. It operates in North America and Europe. Its products and services comprise intellectual property content delivered through various media, including online, journals and books. The Scientific, Technical & Medical segment provides information and tools to help customers in scientific and healthcare outcomes. The Risk & Business Information segment provides data and analytics that enable customers to evaluate and manage risk. The Legal segment is a provider of legal, regulatory and news and business information, and analysis to law firm, corporate, Government and academic customers. The Exhibitions segment includes Reed Exhibitions, which is an exhibitions business.

Receive News & Ratings for Relx PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx PLC and related companies with MarketBeat.com's FREE daily email newsletter.